Supernus Pharmaceuticals Price To Earning vs. Shares Outstanding

SUPN Stock  USD 37.17  0.18  0.49%   
Based on Supernus Pharmaceuticals' profitability indicators, Supernus Pharmaceuticals' profitability may be sliding down. It has an above-average probability of reporting lower numbers next quarter. Profitability indicators assess Supernus Pharmaceuticals' ability to earn profits and add value for shareholders. At this time, Supernus Pharmaceuticals' Days Sales Outstanding is very stable compared to the past year. As of the 9th of December 2024, Operating Cash Flow Sales Ratio is likely to grow to 0.19, while Price To Sales Ratio is likely to drop 2.47. At this time, Supernus Pharmaceuticals' Net Income Per E B T is very stable compared to the past year.
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.820.8621
Notably Down
Slightly volatile
For Supernus Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Supernus Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Supernus Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Supernus Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Supernus Pharmaceuticals over time as well as its relative position and ranking within its peers.
  

Supernus Pharmaceuticals' Revenue Breakdown by Earning Segment

Check out World Market Map.
To learn how to invest in Supernus Stock, please use our How to Invest in Supernus Pharmaceuticals guide.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Supernus Pharmaceuticals. If investors know Supernus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Supernus Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.99)
Earnings Share
1.07
Revenue Per Share
11.877
Quarterly Revenue Growth
0.142
Return On Assets
0.0289
The market value of Supernus Pharmaceuticals is measured differently than its book value, which is the value of Supernus that is recorded on the company's balance sheet. Investors also form their own opinion of Supernus Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Supernus Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Supernus Pharmaceuticals' market value can be influenced by many factors that don't directly affect Supernus Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Supernus Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Supernus Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Supernus Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Supernus Pharmaceuticals Shares Outstanding vs. Price To Earning Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Supernus Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Supernus Pharmaceuticals value to that of its competitors to determine the firm's financial worth.
Supernus Pharmaceuticals is rated below average in price to earning category among its peers. It is rated fourth in shares outstanding category among its peers creating about  3,620,938  of Shares Outstanding per Price To Earning. As of the 9th of December 2024, Common Stock Shares Outstanding is likely to drop to about 42.6 M. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Supernus Pharmaceuticals' earnings, one of the primary drivers of an investment's value.

Supernus Shares Outstanding vs. Price To Earning

Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.

Supernus Pharmaceuticals

P/E

 = 

Market Value Per Share

Earnings Per Share

 = 
15.25 X
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.

Supernus Pharmaceuticals

Shares Outstanding

 = 

Public Shares

-

Repurchased

 = 
55.22 M
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.

Supernus Shares Outstanding Comparison

Supernus Pharmaceuticals is currently under evaluation in shares outstanding category among its peers.

Supernus Pharmaceuticals Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Supernus Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Supernus Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Supernus Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Supernus Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income-593 K-563.4 K
Operating Income-5.3 M-5 M
Income Before Tax2.8 M2.6 M
Total Other Income Expense NetM8.4 M
Net Income1.3 M1.3 M
Income Tax Expense1.5 M1.4 M
Net Income From Continuing Ops25.6 M49 M
Non Operating Income Net Other16.8 M17.7 M
Net Income Applicable To Common Shares69.8 M50.8 M
Interest Income10.9 M12.5 M
Net Interest Income6.9 M7.2 M
Change To Netincome-12.1 M-11.5 M
Net Income Per Share 0.02  0.02 
Income Quality 84.41  88.63 
Net Income Per E B T 0.48  0.50 

Supernus Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Supernus Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Supernus Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Supernus Pharmaceuticals' important profitability drivers and their relationship over time.

Use Supernus Pharmaceuticals in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Supernus Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Supernus Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Supernus Pharmaceuticals Pair Trading

Supernus Pharmaceuticals Pair Trading Analysis

The ability to find closely correlated positions to Supernus Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Supernus Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Supernus Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Supernus Pharmaceuticals to buy it.
The correlation of Supernus Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Supernus Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Supernus Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Supernus Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Supernus Pharmaceuticals position

In addition to having Supernus Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Banks Thematic Idea Now

Banks
Banks Theme
Large and small money and credit banks and credit services. The Banks theme has 48 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Banks Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Supernus Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Supernus Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Supernus Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Supernus Pharmaceuticals Stock:
To fully project Supernus Pharmaceuticals' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Supernus Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Supernus Pharmaceuticals' income statement, its balance sheet, and the statement of cash flows.
Potential Supernus Pharmaceuticals investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Supernus Pharmaceuticals investors may work on each financial statement separately, they are all related. The changes in Supernus Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Supernus Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.